Today's FDA approval of Qsymia has inspired development of a new online community for weight loss patients seeking news and information related to diet plans and weigh gain.
Online PR News – 19-July-2012 – Ocala – The members of the Qsymia Weight Loss Group at Qsymia.me applaud the Food & Drug Administration (FDA) for approving Qsymia, a new obesity treatment medication developed by Vivus, Inc.
Qsymia combines low doses of two agents approved by the FDA, phentermine and topiramate, in a controlled-release formulation.
“Today’s decision by the FDA marks the second new obesity treatment drug within the last 30 days,” said Qsymia Weight Loss Group Executive Director Alfred Moya. “It is plain to see that their is a monumental shift our efforts to address the global obesity epidemic. Obesity health patients are excited about the FDA adding another tool to the obesity treatment toolbox.”
The Qsymia Weight Loss Group is a community forum and message board gathering news and information on Osymia for those interested.
Community members appreciate the careful and thoughtful process taken by the FDA during the review process and we are pleased by the FDA’s approach used during the review of these new obesity treatment medications.